Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study

Lipids in Health and Disease

Nágila RT Damasceno¹  Anelise de Souza Timm²  Isis T da Silva² 

[1] Faculdade de Saúde Pública, Departamento de Nutrição, Av Dr Arnaldo, 715, 01246-904, São Paulo, SP, Brazil;Department of Nutrition, School of Public Health, University of Sao Paulo, Sao Paulo, SP, Brazil

关键词: Obesity;    Cardiovascular risk;    Lp-PLA₂;    Adolescent;   

Others  :  1160073
DOI  :  10.1186/1476-511X-12-19

 received in 2012-07-03, accepted in 2012-12-04,  发布年份 2013

【 摘 要 】

Background

Lipoprotein-associated phospholipase A₂ activity (Lp-PLA₂) is a good marker of cardiovascular risk in adults. It is strongly associated with stroke and many others cardiovascular events. Despite this, the impact of obesity on this enzyme activity and its relation to biomarkers of cardiovascular disease in adolescents is not very well investigated. The purpose of this article is to evaluate the influence of obesity and cardiometabolic markers on Lp-PLA₂ activity in adolescents.

Results

This cross-sectional study included 242 adolescents (10–19 years) of both gender. These subjects were classified in Healthy Weight (n = 77), Overweight (n = 82) and Obese (n = 83) groups. Lipid profile, glucose, insulin, HDL size, LDL(−) and anti-LDL(−) antibodies were analyzed. The Lp-PLA₂ activity was determined by a colorimetric commercial kit. Body mass index (BMI), waist circumference and body composition were monitored. Food intake was evaluated using three 24-hour diet recalls. The Lp-PLA₂ activity changed in function to high BMI, waist circumference and fat mass percentage. It was also positively associated with HOMA-IR, glucose, insulin and almost all variables of lipid profile. Furthermore, it was negatively related to Apo AI (β = −0.137; P = 0.038) and strongly positively associated with Apo B (β = 0.293; P < 0.001) and with Apo B/Apo AI ratio (β = 0.343; P < 0.001). The better predictor model for enzyme activity, on multivariate analysis, included Apo B/Apo AI (β = 0.327; P < 0.001), HDL size (β = −0.326; P < 0.001), WC (β = 0.171; P = 0.006) and glucose (β = 0.119; P = 0.038). Logistic regression analysis demonstrated that changes in Apo B/Apo AI ratio were associated with a 73.5 times higher risk to elevated Lp-PLA₂ activity.

Conclusions

Lp-PLA₂ changes in function of obesity, and that it shows important associations with markers of cardiovascular risk, in particular with waist circumference, glucose, HDL size and Apo B/Apo AI ratio. These results suggest that Lp-PLA₂ activity can be a cardiovascular biomarker in adolescence.

【 授权许可】

   
2013 da Silva et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 1.

【 参考文献 】

• [1]Ogden, Cynthia, and Margaret Carroll: "Prevalence of obesity among children and adolescents: United States, trends 1963–1965 through 2007–2008.". Centers for Disease Control and Prevention. National Center for Health Statistics, Atlanta; 2010. http://www.cdc.gov/nchs/data/hestat/obesity_child_07_08/obesity_child_07_08.htm webcite
• [2]IBGE: Antropometria e Análise do estado nutricional de crianças e adolescentes no Brasil. Pesquisa de orçamentos familiares, 2002–2003. 2006. http://www.ibge.gov.br/home/presidencia/noticias/noticia_visualiza.php?id_noticia=1699&id_pagina=1 webcite 2010
• [3]Fiedman JM: Obesity in the new millennium. Nature 2000, 404:632-634.
• [4]Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4-7.
• [5]Linna MS, Borg P, Kukkonen-Harjula K, Foglholm M, Nenonem A, Ahotupa M, Vasankari TJ: Successful weight maintenance preserves lower levels of oxidized LDL achieved by weight reduction in obese men. Int J Pediatr Obes 2007, 31:245-253.
• [6]Holvoet P: Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008, 70:193-219.
• [7]SEARCH for Diabetes in Youth Study Group: The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study. Pediatrics 2006, 118:1510-1518.
• [8]CDC(Center for Disease Control): Prevalence of Abnormal Lipid Levels among Youths — United States, 1999–2006. Weekly 2010, 59:29-64.
• [9]Celik T, Iyisoy A, Yuksel UC, Isik E: The role of abdominal obesity and weight gain since adolescence in early atherosclerosis. Int J Cardiol 2009, 132:263-295.
• [10]The Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
• [11]Karabina S, Ninio E: Plasma PAF-acetylhydrolase: An unfulfilled promise? Biochim Biophys Acta 2006, 1761:1351-1358.
• [12]Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M: Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 2005, 72:203-209.
• [13]Tselepis AD, Chapmam MJ: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase. Atherosclerosis 2002, 3:57-68.
• [14]Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J: Electronegative low-density lipoprotein. Curr Opin Lipidol 2004, 15:329-335.
• [15]Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G: The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007, 190:388-396.
• [16]Okamura K, Miura S, Zhang B, Uehara Y, Matsuo K, Kumagai K, Saku K: Ratio of LDL- to HDL-Associated Platelet-Activating Factor Acetylhydrolase may be a Marker of Inflammation in Patients With Paroxysmal Atrial Fibrillation. Circ J 2007, 71:214-219.
• [17]Madjid M, Ali M, Willerson JT: Lipoprotein-Associated Phospholipase A2 as a Novel Risk Marker for Cardiovascular Disease. Tex Heart Inst J 2010, 37:25-39.
• [18]WHO (World Health Organization): Nutrition in adolescence Issues and Challenges for the Health Sector. WHO, Geneva; 2005.
• [19]Sociedade Brasileira de Hipertensão: IV Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cardiol 2004, 82(IV):7-14.
• [20]Cole T, Bellizze MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000, 320:1-6.
• [21]Cole T, Flegal KM, Nicholls D, Jackson AA: Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ 2007, 335:1-9.
• [22]UNIFESP - Nutrition Data System NDS®: Food and Nutrient Database version 35. Regent of the University of Minnesota; 2005. http://www.unifesp.br/dis/produtos/nutwin/index.htm webcite
• [23]Willett W, Stampfer M: Implications of total energy intake for epidemiologic analysis. Nutritional epidemiology. 2nd edition. Oxford University Press, New York; 1998.
• [24]Mackerras D: Energy adjustment the concepts underlying the debate. J Clin Epidemiol 1996, 49:957-962.
• [25]Nusser SM, Carriquiry AL, Dodd KW, et al.: A Semiparametric Transformation Approach to estimating Usual Daily Intake distributions. J Am Stat Assoc 1996, 91:1440-1449.
• [26]Marshall WA: Variations in pattern of pubertal changes in girls. Arch Dis Childhood 1969, 44:291-303.
• [27]Marshall WA, Tanner JM: Variations in pattern of pubertal changes in boys. Arch Dis Childhood 1970, 44:13-23.
• [28]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [29]Lima ES, Maranhão RC: Rapid, Simple Laser-Light-Scattering Method for HDL Particle Sizing in Whole Plasma. Clin Chem 2004, 50(6):1086-1088.
• [30]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985, 28:412-419.
• [31]Damasceno N, Sevanian A, Apolinário E, Oliveira J, Fernandes I, Abdalla D: Detection of electronegative low density lipoprotein (LDL) in plasma and atherosclerotic lesions by monoclonal antibody-based immunoassays. Clin Biochem 2006, 39:28-38.
• [32]Damasceno NRT, Apolinario E, Fernandes I, Flauzino FD, Abdalla DSP: Soy isoflavones reduce electronegative low density lipoprotein (LDL-) and anti-LDL- autoantibodies in experimental atherosclerosis. Eur J Nutr 2007, 46:125-132.
• [33]Taylor SA, Hergenroeder AC: Waist circumference predicts increased cardiometabolic risk in normal weight adolescent males. Int J Pediatr Obes 2012, 6:307-311.
• [34]Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB: Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr 2010, 91:786-793.
• [35]Tsimihodimos V, Karabina SP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD: Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB. Arterioscler Thromb Vasc Biol 2002, 22:306-311.
• [36]Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS: Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome. Lipids 2008, 44:9-16.
• [37]Pascot A, Lemieux I, Prud’homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Després JP: Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. Lipid Res 2001, 42:2007-2014.
• [38]Medina-Urrutia A, Juarez-Rojas JG, Martínez-Alvarado R, Jorge-Galarza E, Posadas-Sánchez R, Cardoso-Saldaña G, Caracas-Portilla N, Mendoza-Perez E, Posadas-Romero C: High-density lipoprotein subclasses distribution and composition in Mexican adolescents with low HDL cholesterol and/or high triglyceride concentrations, and its association with insulin and c-reactive protein. Atherosclerosis 2008, 201:392-397.
• [39]Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S: Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009, 30:107-115.
• [40]Li N, Li S, Yu C, Gu S: Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort. Postgrad Med 2010, 122:200-205.
• [41]Sabatine MS, Morrow DA, O’Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J: Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. Arterioscler Thromb Vasc 2007, 27:2463-2469.
• [42]Okada T, Miyashita M, Kuromori Y, Iwata F, Harada K, Hattori H: Platelet-Activating Factor Acetylhydrolase Concentration in Children With Abdominal Obesity. Arterioscler Thromb Vasc Biol 2006, 26:40-e41.
• [43]Castro SH, Faria Neto HCC, Gomes MB: Platelet-Activating Factor Acetylhydrolase (PAF-AH) Activity in Patients with Type 1 Diabetes Mellitus. Arq Bras Cardiol 2007, 88:179-184.
• [44]Nagel G, Rapp K, Wabitsch M, Buchele G, Kroke A, Zollner I, Weiland SK, Koenig W: Prevalence and Cluster of Cardiometabolic Biomarkers in Overweight and Obese Schoolchildren: Results from a Large Survey in Southwest Germany. Clin Chem 2008, 54:2317-2325.
• [45]Motykova E, Zlatohlavek L, Prusikova M, Lanska V, Ceska R, Vasickova L, Vrablik M: Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children. Neuro Endocrinol Lett 2011, 32(Suppl 2):55-59.
• [46]Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A: Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals. Clin Chem 2004, 50:2077-2082.
• [47]Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, Ni H, Boerwinkle E, Mosley T, Sharrett R, Folsom AR, Ballantyne CM: Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2009, 40:376-381.